ADEL-Y01
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Human
ADEL-Y01 (50 mg/kg; i.p.; weekly; 3 months) ameliorates behavioral deficits and pathological tau changes in Tau-P301L-transgenic mice, with antibody crossing the blood-brain barrier to target tau-acK280[2].
ADEL-Y01 (50 mg/kg; i.p.; weekly; 3 months) improves cognitive performance and reduces tau aggregates in Tau-P301S-transgenic mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Tau-P301L-transgenic (backcrossed to C57BL/6J over five generations; male and female; 8 months old at start)[2]
-
Dosage:1.9 mg/mL
-
Administration:i.c.v.; continuous infusion; 28 days
-
Result:Improved performance in nest building, Y-maze, water maze, and grip strength tests.
Reduced insoluble tau levels in mouse brains.
Decreased total tau (tau-5), tau-pS396, and tau-acK280 levels in cortex lysate western blots.
Normalized increased phosphorylated tau levels via immunohistochemistry.
Showed a non-statistically significant trend toward reversal of tau-Tg-associated decreases in synaptic proteins (PSD95, synapsin-1).
-
Animal Model:Tau-P301L-transgenic (backcrossed to C57BL/6J over five generations; 7 or 14 months old at start)[2]
-
Dosage:50 mg/kg
-
Administration:i.p.; weekly; 3 months
-
Result:Improved performance in nest building, Y-maze, and Morris water maze tests.
Entered the brain and bound to tau-acK280.
Decreased total tau (tau-5), tau-pT231, and tau-acK280 aggregate levels in semi-denatured western blots of cortex lysates.
Showed a non-statistically significant trend toward reversal of tau-Tg-associated decreases in synaptic proteins (PSD95, synapsin-1).
-
Animal Model:Tau-P301S-transgenic (backcrossed to C57BL/6J over five generations; 5 months old at start)[2]
-
Dosage:5 mg/kg; 50 mg/kg
-
Administration:i.p.; weekly; 3 months
-
Result:Improved performance in the Morris water maze test at 50 mg/kg dose.
Decreased levels of total tau (tau-5) and tau-acK280 monomers and oligomers/aggregates in semi-denatured western blots of formic acid-fractionated hippocampus lysates at 50 mg/kg dose.
No quantitative results reported for the 5 mg/kg dose.
Tau
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ADEL-Y01 Related Classifications
HY-P992172 Related Classifications
Powered by Bioz